Growth inhibitory role of the p53 activator SCH 529074 in non‑small cell lung cancer cells expressing mutant p53

Nenkov,Miljana; Ma,Yunxia; Haase,Daniela; Zhou,Zhongwei; Li,Yong; Petersen,Iver; Lu,Guanghua; Chen,Yuan

doi:10.3892/or.2020.7546

Growth inhibitory role of the p53 activator SCH 529074 in non‑small cell lung cancer cells expressing mutant p53

Authors:
- Miljana Nenkov
- Yunxia Ma
- Daniela Haase
- Zhongwei Zhou
- Yong Li
- Iver Petersen
- Guanghua Lu
- Yuan Chen
View Affiliations

Affiliations: Section Pathology of The Institute of Forensic Medicine, University Hospital Jena, Friedrich Schiller University, D‑07747 Jena, Germany, Leibniz Institute on Ageing‑Fritz Lipmann Institute (FLI), D‑07745 Jena, Germany, Institute of Pathology, SRH Wald‑Klinikum, D‑07548 Gera, Germany, School of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, P.R. China
Published online on: March 17, 2020 https://doi.org/10.3892/or.2020.7546
Pages: 2073-2082

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mutations of p53 occur in approximately 50% of advanced non‑small cell lung cancer (NSCLC) cases, leading to loss of tumor suppressive function and/or gain of p53 oncogenic activity. Reactivation of mutant p53 and consequently induction of apoptosis in cancer cells is the goal of p53‑targeted therapy. Recently, several p53 mutant reactivating compounds were discovered including SCH 529074. However, the role of SCH 529074 in NSCLC has not been fully explored. In the present study, the effects of this compound on cell survival, cell cycle progression, induction of apoptosis and modulation of cell signaling in p53 mutant NSCLC cells (H1975, H322 and H157) and p53 wild‑type NSCLC cells (A549), was investigated. Cell‑based functional assays, real‑time RT‑qPCR and western blot assays were used. HCT116 [p53 wild‑type (WT)] and HCT116 p53‑/‑ (p53 null) were used as control cells. The results demonstrated that SCH 529074 treatment caused significant reduction in cell viability and colony formation activity in p53 mutant, p53 WT and p53‑deficient cells. The treatment of NSCLC cells with SCH 529074 resulted in a dose‑dependent induction of apoptosis and G0/G1 cell cycle arrest, which was associated with the activation of caspases (3 and 7), p53‑independent upregulation of p21 and PUMA as well as increased LC3II, a biomarker of autophagy. The combination treatment with the autophagy inhibitor chloroquine (CQ) and SCH 529074 led to decreased cell viability, colony formation and increased induction of apoptosis. The data indicated that SCH 529074 may exert its growth inhibitory function in a p53‑independent manner in NSCLC cells.

View Figures

View References

1	Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current therapies and new targeted treatments. Lancet. 389:299–311. 2017. View Article : Google Scholar
2	Oser MG, Niederst MJ, Sequist LV and Engelman JA: Transformation from non-small-cell lung cancer to small-cell lung cancer: Molecular drivers and cells of origin. Lancet Oncol. 16:e165–e172. 2015. View Article : Google Scholar :
3	Mascaux C, Tomasini P, Greillier L and Barlesi F: Personalised medicine for nonsmall cell lung cancer. Eur Respir Rev. 26:1700662017. View Article : Google Scholar
4	Lin Y, Wang X and Jin H: EGFR-TKI resistance in NSCLC patients: Mechanisms and strategies. Am J Cancer Res. 4:411–435. 2014.
5	Green DR and Chipuk JE: p53 and metabolism: Inside the TIGAR. Cell. 126:30–32. 2006. View Article : Google Scholar
6	Mogi A and Kuwano H: TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol. 2011:5839292011. View Article : Google Scholar :
7	Brosh R and Rotter V: When mutants gain new powers: News from the mutant p53 field. Nat Rev Cancer. 9:701–713. 2009. View Article : Google Scholar
8	Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ and Sculier JP: Role of p53 as a prognostic factor for survival in lung cancer: A systematic review of the literature with a meta-analysis. Eur Respir J. 18:705–719. 2001. View Article : Google Scholar
9	Yue X, Zhao Y, Xu Y, Zheng M, Feng Z and Hu W: Mutant p53 in cancer: Accumulation, gain-of-function and therapy. J Mol Bio. 429:1595–1606. 2017. View Article : Google Scholar
10	Demma M, Maxwell E, Ramos R, Liang L, Li C, Hesk D, Rossman R, Mallams A, Doll R, Liu M, et al: SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J Bio Chem. 285:10198–10212. 2010. View Article : Google Scholar
11	Parrales A and Iwakuma T: Targeting oncogenic mutant p53 for cancer therapy. Front Oncol. 5:2882015. View Article : Google Scholar :
12	Cui T, Chen Y, Yang L, Knösel T, Zöller K, Huber O and Petersen I: DSC3 expression is regulated by p53, and methylation of DSC3 DNA is a prognostic marker in human colorectal cancer. Br J Cancer. 15:1013–1019. 2011. View Article : Google Scholar
13	Li Y, Chen Y, Ma Y, Nenkov M, Haase D and Petersen I: Collagen prolyl hydroxylase 3 has a tumor suppressive activity in human lung cancer. Exp Cell Res. 363:121–128. 2018. View Article : Google Scholar
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
15	Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc. 1:2315–2319. 2006. View Article : Google Scholar
16	Weinberg RA: p53 and apoptosis: Master guardian and executioner. The Biology of Cancer. Garland Science, Taylor & Francis Group; New York, NY: pp. 331–389. 2014
17	Levine B and Abrams J: p53: The Janus of autophagy? Nat Cell Biol. 10:637–639. 2008. View Article : Google Scholar :
18	Tanida I, Ueno T and Kominami E: LC3 and autophagy. Methods Mol Biol. 445:77–88. 2008. View Article : Google Scholar
19	Zhou X, Hai Q and Lu H: Mutant p53 in cancer therapy-the barrier or the path. J Mol Cell Biol. 11:293–305. 2019. View Article : Google Scholar
20	Lee YS, Yoon S, Park MS, Kim JH, Lee JH and Sonog CW: Influence of p53 expression on sensitivity of cancer cells to bleomycin. J Biochem Mol Toxicol. 24:260–269. 2010. View Article : Google Scholar
21	Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG and Selivanova G: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 8:282–288. 2002. View Article : Google Scholar
22	Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003. View Article : Google Scholar :
23	Karimian A, Ahmadi Y and Yousefi B: Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst). 42:63–71. 2016. View Article : Google Scholar
24	Jeong JH, Kang SS, Park KK, Chang HW, Magae J and Chang YC: p53-independent induction of G1 arrest and p21WAF1/CIP1 expression by ascofuranone, an isoprenoid antibiotic, through downregulation of c-Myc. Mol Cancer Ther. 9:2102–2113. 2010. View Article : Google Scholar
25	Arachchige Don AS, Dallapiazza RF, Bennin DA, Brake T, Cowan CE and Horne MC: Cyclin G2 is a centrosome-associated nucleocytoplasmic shuttling protein that influences microtubule stability and induces a p53-dependent. Exp Cell Res. 312:4181–4204. 2006. View Article : Google Scholar :
26	Sun GG, Zhang J and Hu WN: CCNG2 expression is down-regulated in colorectal carcinoma and its clinical significance. Tumour Biol. 35:3339–3346. 2014. View Article : Google Scholar
27	Strasser A, Harris AW, Jacks T and Cory S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell. 79:329–339. 1994. View Article : Google Scholar
28	Montero J and Letai A: Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ. 25:56–64. 2018. View Article : Google Scholar
29	Yu J and Zhang L: PUMA, a potent killer with or without p53. Oncogene. 27 (Suppl 1):S71–S83. 2008. View Article : Google Scholar :
30	Wu B, Qiu W, Wang P, Yu H, Cheng T, Zambetti GP, Zhang L and Yu J: p53 independent induction of PUMA mediates intestinal apoptosis in response to ischaemia-reperfusion. Gut. 56:645–654. 2007. View Article : Google Scholar
31	Ambroise G, Portier A, Roders N, Arnoult D and Vazquez A: Subcellular localization of PUMA regulates its pro-apoptotic activity in Burkitt's lymphoma B cells. Oncotarget. 6:3818–3894. 2015. View Article : Google Scholar
32	Zheng X, He K, Zhang L and Yu J: Crizotinib induces PUMA-dependent apoptosis in colon cancer cells. Mol Cancer Ther. 12:777–786. 2013. View Article : Google Scholar :
33	Hafner A, Bulyk ML, Jambhekar A and Lahav G: The multiple mechanisms that regulate p53 activity and cell fate. Nat Rev Mol Cell Biol. 20:199–210. 2019. View Article : Google Scholar
34	Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, et al: Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer. 59:329–332. 2012. View Article : Google Scholar
35	Cordani M, Butera G, Pacchiana R and Donadelli M: Molecular interplay between mutant p53 proteins and autophagy in cancer cells. Biochim Biophys Acta Rev Cancer. 1867:19–28. 2017. View Article : Google Scholar
36	Mizushima N and Yoshimori T: How to interpret LC3 immunoblotting. Autophagy. 3:542–545. 2007. View Article : Google Scholar
37	Huang S and Sinicrope FA: Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy. 6:256–269. 2010. View Article : Google Scholar :
38	Matlock K, Berlow N, Keller C and Pal R: Combination therapy design for maximizing sensitivity and minimizing toxicity. BMC Bioinformatics. 18 (Suppl 4):S1162017. View Article : Google Scholar